深圳商报·读创客户端记者 宁可坚 近日，江西齐云山食品股份有限公司（简称"齐云山"）向港交所递交招股书，独家保荐人为中泰国际。 公司的股权结构比较简单，IPO前，崇义食品厂持股75%，崇义食品厂股东、公司雇员出资的云之上有限合伙持股25%。 "头把交椅"背后产品依赖单一 根据招股书，齐云山是一家专注于南酸枣食品产品的果类零食公司，于1992年推出其第一款南酸枣糕产品。目前，齐云山推出了5种南酸枣食品产 品，除了南酸枣糕，还有南酸枣粒、南酸枣凝、南酸枣软糖及南酸枣冻。 根据灼识咨询的资料，以2024年零售额计，齐云山占中国南酸枣食品市场32.4%的份额，稳坐行业头把交椅。 2022年~2024年，齐云山食品的总营收持续增长，分别达到2.17亿元、2.47亿元和3.39亿元，2024年同比增长40.8%；年内净利润分别为2563.4万 元、2370.5万元和5319.9万元，2024年同比增长124.42%，其营收和净利润均在2024年增长迅猛。 | | 2022财年 | 2023財年 | 2024財年 | | --- | --- | --- | --- | | | 人民幣千元 | 人民幣千元 | 人民幣千元 | ...

Core Viewpoint - Saintong Special Medical, a supplier of medical food, is seeking to list on the Hong Kong Stock Exchange, showcasing strong revenue growth but facing challenges due to high dependency on a single product line and low R&D investment [2][4][15]. Financial Performance - Saintong Special Medical has maintained a high gross margin of 71% over the years, with projected revenues increasing from RMB 4.91 billion in 2022 to RMB 8.34 billion in 2024, representing a 1.7 times growth over three years [8][9]. - The net profit margin is relatively low at 11.3%, with net profits of RMB 0.84 billion, RMB 1.7 billion, and RMB 0.94 billion for the years 2022 to 2024 respectively [16][15]. Revenue Structure - Over 90% of the company's revenue comes from allergy prevention products, with this segment's contribution increasing from 85.5% in 2022 to 90.3% in 2024 [8][9]. - Other product lines, such as premature infant products and lactose-free products, contribute less than 10% to total revenue [9]. R&D and Marketing Expenditure - The company has allocated less than 2% of its revenue to R&D, with expenditures of RMB 6.51 million, RMB 10.81 million, and RMB 13.30 million from 2022 to 2024, while marketing expenses have been significantly higher [13][15]. - Marketing expenses accounted for approximately 39% to 41% of total revenue during the same period [13]. Market Position - Saintong Special Medical holds a 9.5% market share in the domestic infant medical food market, ranking third, while its overall market share in the medical food sector is only 6.3% [14]. - The company faces intense competition from both domestic and international firms, with the top three competitors holding a combined market share of nearly 70% [14]. Inventory Management - The inventory turnover days have increased significantly, from 54 days in 2022 to 155 days in 2024, indicating potential inefficiencies in inventory management [14]. Dividend Policy - The company has been generous with dividends, distributing a total of RMB 4.67 billion from 2022 to March 2023, despite low R&D investment [15][17]. Listing Pressure - Saintong Special Medical is under pressure to meet certain conditions related to its IPO, including the potential restoration of special rights for investors if the listing is not successful by the end of 2026 [18].